In this article (Clin Cancer Res 2012;18:1735–42), which was published in the March 15, 2012, issue of Clinical Cancer Research (1), the paragraph in the Patients and Methods section on page 1738, “The region of interest was the measurable target lesion in the primary tumor with maximal 3.0-cm diameter volume SUV [Lesion 1-SUVmax (3 cm)] on the baseline scan. Lesion 1-SUVmax (3 cm) was adjusted to lean body mass [Lesion 1-SUV-LBMmax (3 cm)] and normalized to the average liver SUV-LBMmax (3 cm). A metabolic response was defined as a 30% or greater change in adjusted Lesion 1-SUV-LBMmax (3 cm) when values from days 14 and 120 were compared with the baseline values,” has been changed to “A 3-cm diameter volume of interest was placed over the measurable target lesion in the primary tumor and the maximum single voxel SUV determined [Lesion 1-SUVmax (3 cm)] on the baseline scan. Lesion 1-SUVmax (in the 3-cm VOI) was adjusted to lean body mass [Lesion 1-SUV-LBMmax (within 3-cm VOI)] and normalized to the average liver SUV-LBMmax at the time of each study (3-cm VOI). A metabolic response was defined as a 30% or greater decline in adjusted Lesion 1-SUV-LBMmax (within the 3-cm tumor VOI) when values from days 14 and 120 were compared with the baseline values.”

The title for Table 7 on page 1740, “Percent change in adjusted SUV-LBM (3 cm), by treatment group,” has been changed to “Percent change in adjusted SUV-LBM (max), by treatment group.”

An author has been added to the article because of the significant contribution of his work in the final product. The following author has been added:

Muhammad A. Chaudhry, Tawam Molecular Imaging Center, Abu Dhabi, United Arab Emirates.

The list of authors now reads as follows:

Jill Gilbert, Michelle A. Rudek, Michaela J. Higgins, Ming Zhao, Sara Bienvenu, Nancy Tsottles, Muhammad A. Chaudhry, Richard Wahl, Arlene Forastiere, and Maura Gillison.

The authors regret these errors.

1.
Gilbert
J
,
Rudek
MA
,
Higgins
MJ
,
Zhao
M
,
Bienvenu
S
,
Tsottles
N
, et al
A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck
.
Clin Cancer Res
2012
;
18
:
1735
42
.